[tacticalogic]

I'm not familiar enough with the subject to pass judgement on the research itself. I do take exception to "cherry picking" data points in order to advance an agenda. It's a favorite tactic of the liberals, and one we'd do well to avoid, IMHO.

[Al B.]

I do take exception to "cherry picking" data points in order to advance an agenda. It's a favorite tactic of the liberals, and one we'd do well to avoid, IMHO.

In this case, unfortunately, the agenda and cherry-picking  are the property of Merck.  The original news story on this "study" was done by a writer who admitted to me that he got some of his data from Merck.  He also relied on information in a Merck press release about a licensing agreement on a new class of schizophrenia drugs they are working on that impact cannabinoid receptors.  This study is just another piece of pre-marketing propaganda to help Merck make their case for this new class drugs to treat schizophrenia.